Career history of Joan Sellers
Former positions of Joan Sellers
| Companies | Position | Start | End |
|---|---|---|---|
| Targeted Cell Therapies LLC | Corporate Officer/Principal | 2009-12-31 | 2009-12-31 |
| Vasculogic LLC | Founder | 2005-12-31 | 2005-12-31 |
| President | - | 2005-12-31 | |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 1993-12-31 | 1993-12-31 |
| NANOMIX CORPORATION | Chief Tech/Sci/R&D Officer | 2011-04-05 | - |
Training of Joan Sellers
| State University of New York at Albany | Doctorate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Commercial Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
| Targeted Cell Therapies LLC | |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Vasculogic LLC |
- Stock Market
- Insiders
- Joan Sellers
- Experience
